By Lizzy | Posted - Jun 25th, 2016





CLINICAL TRIAL: YELIVA For Relapsed/Refractory Myeloma

A new drug called YELIVA™ (ABC294640) is an oral drug that is a kinase inhibitor that has anticancer and anti-inflammatory effects. In June 2016, Duke University Medical Center (Durham, North Carolina) will begin recruiting about 56 relapsed or refractory multiple myeloma patients for its Phase Ib/II study of YELIVA (ABC2940). The clinical trial will evaluate the safety and efficacy of YELIVA as a single-agent. Patients must have been previously treated with protease inhibitors (bortezomib or carfilzomib) and immunomodulatory agents (thalidomide, lenalidomide or pomalidomide), and have active, measurable disease. The starting dose given is known to be safely tolerated as a single agent. As part of the study, the dose will increase. The trial is an "interventional trial" and will be used to actively treat participants' myeloma. This trial is supported by a $2 million grant from the National Cancer Institute (NCI). The Phase II study to evaluate YELIVA as a protectant against the toxic effect of mucositis in cancer patients undergoing radiation is planned to be initiated in the second half of 2016. YELIVA is also being studied for use in treating several cancers, including  solid tumor cancers. For more information about YELIVA, click . For more information on the YELIVA Phase Ib/II study for relapsed or refractory myeloma, visit the SparkCures site here: SparkCures Clinical Trial YELIVA (ABC294640)    

About the Author

Lizzy - Lizzy Smith was diagnosed with myeloma in 2012 at age 44. Within days, she left her job, ended her marriage, moved, and entered treatment. "To the extent I'm able, I want to prove that despite life's biggest challenges, it is possible to survive and come out stronger than ever," she says.



Thanks to our site sponsors:

Takeda Oncology Celgene Adaptive biotechnologies